Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein.
about
Novel approaches to identify protective malaria vaccine candidatesGlycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentPlasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependentThe Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian AmazonThe Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic VariantsStructural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine designAntibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoitesSingle-chain antibody fragment specific for Plasmodium vivax Duffy binding protein.Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon.Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies.Determination of the molecular basis for a limited dimorphism, N417K, in the Plasmodium vivax Duffy-binding protein.Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine developmentAdvances and challenges in malaria vaccine development.Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand.Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria.Genetic variability and natural selection at the ligand domain of the Duffy binding protein in Brazilian Plasmodium vivax populations.The epitope of monoclonal antibodies blocking erythrocyte invasion by Plasmodium falciparum map to the dimerization and receptor glycan binding sites of EBA-175.Immunity to asexual blood stage malaria and vaccine approaches.Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding proteinAntibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmissionDuffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity.Naturally-acquired cellular immune response against Plasmodium vivax merozoite surface protein-1 paralog antigen.Measurement of antibody levels against region II of the erythrocyte-binding antigen 175 of Plasmodium falciparum in an area of malaria holoendemicity in western KenyaDesign and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein.Plasmodium simium, a Plasmodium vivax-related malaria parasite: genetic variability of Duffy binding protein II and the Duffy antigen/receptor for chemokines.Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies.Genetic polymorphism and natural selection of Duffy binding protein of Plasmodium vivax Myanmar isolates.Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II.Duffy Blood Group System and the malaria adaptation process in humansThe Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax.A pregnant Japanese woman returning from Africa with recurrent fevers.Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.Identification of a reticulocyte-specific binding domain of Plasmodium vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain.The risk of malarial infections and disease in Papua New Guinean children.A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive Reticulocytes.Approaches to malaria vaccine development using the retrospectroscope.Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA) binds human erythrocytes independent of Duffy antigen status.Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition.
P2860
Q21131082-6FB2E000-F9F2-4D81-94BB-1A6D96CB9C24Q21558777-BC3D09F9-D9DB-4874-9B18-FC62C1E956E7Q24596355-5A25D509-65A1-4F79-9DAE-CB04B08D70A6Q27009149-E22B2F12-50BD-4ED2-851D-085E7F0E168BQ28396379-3476BD93-F85E-47B0-8FDF-731AFAAAF56BQ28544738-3F463E09-117E-4D5E-8FE9-A1F077E8BAC9Q30845059-78B03F13-CBC1-4523-86C3-5E4AFA8CBBD2Q33282823-9AA9E2EA-6C7D-4E30-A0EE-E59FF0993A71Q33530114-DECB9732-E5A9-4098-B3D5-EE0A9471C1ACQ33617528-A0125D2C-365D-49B9-9D40-037170FF6963Q33676028-7E993CB2-FD45-4C3C-8AC2-BC2BE969E09BQ33918156-6C84FE55-6379-4790-BCC5-02E469D1D53BQ33988630-66543099-0ED9-46F3-8332-D20B3F36E6FFQ34145333-25F77B12-55E1-4C48-BC6A-E86B95C82D5CQ34256740-3DC7C5A8-59B8-46EF-A9AF-886C6FE1A90DQ34260750-39F64471-7ACD-4967-ADF4-F0F2C9D6F1C4Q34303373-3DC3284B-888A-41E7-A86F-401FC4AB61BCQ34413915-06B3CAE6-0CC7-4C72-904A-E47C979488F2Q34606720-BB50D2C3-8ADB-4145-BA39-0B2C3B794DACQ34842236-E02124A8-1EF5-4246-B98F-3A1C6322C666Q34994491-DEE1B695-7ABF-4B71-B250-0496B0C2A00BQ35031922-DC8C472B-E45D-4287-94E3-3494383E19E8Q35141958-48CB64B2-2343-49F2-B1EA-F65EB553EAFBQ35494820-E3D65A62-F4E4-42A7-B843-0052B2CBE03EQ35550197-097CAB5F-6BE4-46DB-95CE-A671B8BD8F31Q35666191-F1C4C108-A4EF-44E9-B642-D8BB25773304Q35673121-52477740-EA5B-412A-A74D-CEE1865B5152Q35805433-9D4786B3-EF55-4D79-A8DC-DCDE2DE11AB9Q35980285-1F99AACD-77A5-4313-B62D-7E1F90396CDEQ36008345-2301B55A-312B-436A-9D6F-95A5CB5AA5EEQ36464343-799B6077-B940-41F5-87B5-6B6569D894EEQ36826946-56B58660-7F00-4F9E-8617-5E499AEE06B3Q36856606-FB56F8BC-68A4-4AC1-B811-A0E7C9C18BD9Q36867704-555E8042-8393-4CF8-84EC-708C26CC0E8EQ36950470-F4563225-352C-4B71-ADD3-6573F9C82A1CQ37088901-26928A1B-4A43-4D61-9AB8-EE531C00DEFEQ37208395-2EA19CDA-E148-41E1-8D17-0D6551DF1367Q37274832-E979F934-9CD8-4B8D-ABCC-E5A7D3718F73Q37349102-DF373538-2EA2-4A70-8CD1-74ABFE82EE54Q37595658-3EF18523-EAF2-4DC5-8291-3C4F5B8B3F5B
P2860
Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@ast
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@en
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@nl
type
label
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@ast
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@en
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@nl
prefLabel
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@ast
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@en
Naturally acquired and vaccine ...... m vivax Duffy binding protein.
@nl
P2860
P1476
Naturally acquired and vaccine ...... um vivax Duffy binding protein
@en
P2093
P2860
P304
P356
10.1128/IAI.68.6.3164-3171.2000
P407
P577
2000-06-01T00:00:00Z